Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review. Issue 12 (26th September 2021)

• Record Type: Journal Article
• Authors: Liu, Lucy Y.; Teng, Joyce M. C.; Spunt, Sheri L.; Strelo, Jenna L.; Kwong, Bernice Y.; Zaba, Lisa C.
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 12(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-09-26
• Subjects: cancer -- cutaneous -- immunotherapy -- oncodermatology -- pediatric -- targeted therapy; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29346
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Cutaneous adverse events (cAEs) from targeted antineoplastic agents and immune checkpoint inhibitors are common in children with cancer and may lead to dose reduction or cessation of critical oncologic treatment. Timely diagnosis and proper management of cAEs in pediatric oncology patients is essential to optimize ongoing cancer‐directed therapy and improve quality of life. This systematic review of published studies summarizes dermatologic toxicities to targeted anticancer treatments and immune checkpoint inhibitors.